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The overlapping expression profile of MEF2 and the
class-II histone deacetylase, HDAC7, led us to investi-
gate the functional interaction and relationship be-
tween these regulatory proteins. HDAC7 expression in-
hibits the activity of MEF2 (-A, -C, and -D), and in
contrast MyoD and Myogenin activities are not affected.
Glutathione S-transferase pulldown and immunopre-
cipitation demonstrate that the repression mechanism
involves direct interactions between MEF2 proteins and
HDAC7 and is associated with the ability of MEF2 to
interact with the N-terminal 121 amino acids of HDAC7
that encode repression domain 1. The MADS domain of
MEF2 mediates the direct interaction of MEF2 with
HDAC7. MEF2 inhibition by HDAC7 is dependent on the
N-terminal repression domain and surprisingly does not
involve the C-terminal deacetylase domain. HDAC7 in-
teracts with CtBP and other class-I and -II HDACs sug-
gesting that silencing of MEF2 activity involves core-
pressor recruitment. Furthermore, we show that
induction of muscle differentiation by serum with-
drawal leads to the translocation of HDAC7 from the
nucleus into the cytoplasm. This work demonstrates
that HDAC7 regulates the function of MEF2 proteins
and suggests that this class-II HDAC regulates this im-
portant transcriptional (and pathophysiological) target
in heart and muscle tissue. The nucleocytoplasmic traf-
ficking of HDAC7 and other class-II HDACs during myo-
genesis provides an ideal mechanism for the regulation
of HDAC targets during mammalian development and
differentiation.
Skeletal muscle has become a model for understanding many
fundamental principles of development. Differentiation of pre-
cursor cells into skeletal muscle cells involves two events, de-
termination into myoblasts and the formation of postmitotic,
multinucleated myotubes with contractile phenotype. These
processes are under control of members of the MyoD family of
basic-helix-loop-helix (bHLH)1 transcription factors (MyoD,
Myf5, Myogenin, and MRF4). These proteins can inhibit cell
proliferation, regulate a cascade of muscle-specific gene expres-
sion, auto- and cross-regulate their own and each other’s ex-
pression, and induce muscle differentiation in nonmuscle cells
(1–3). Myogenic bHLH proteins activate transcription of mus-
cle-specific genes by forming heterodimers with other, ubiqui-
tously expressed bHLH proteins known as E2A proteins (alter-
natively spliced products of the E2A gene) (4–7). These
heterodimers bind to the E box motif (CANNTG), which func-
tions as the cognate binding site in the regulatory regions of
most muscle genes (1, 3, 8). MyoD and Myf5 are required for
determination of precursor cells into myoblasts (9), whereas
Myogenin is specifically required for differentiation (10, 11).
Therefore myoD and myf5 are expressed in proliferating myo-
blasts and are markers for commitment, whereas the expres-
sion of myogenin is a marker of terminal-differentiation.
Even though members of the MyoD family are the key reg-
ulators of muscle differentiation, the activation of muscle-spe-
cific genes is dependent on the association with members of the
MEF2 (myocyte enhancer factor 2) (12) family of transcription
factors (8). MEF2 proteins cooperatively increase the activity of
myogenic bHLH transcription factors (13). In vertebrates the
MEF2 family is encoded by four independent genes, mef2a,
mef2b, mef2c, and mef2d (13). MEF2 factors belong to the
MADS-(MCM1-agamous deficiens-serum response factor) box
family and share a highly conserved 86-amino acid-region that
encodes the MADS and MEF2 domains, which mediate DNA
binding and dimerization, respectively (2). Loss-of-function
mutations in the single Drosophila mef2 gene prevent myoblast
differentiation (14, 15), and dominant-negative MEF2 mutants
inhibit myoblast differentiation in cell culture (16) demonstrat-
ing a critical role of MEF2 proteins in terminal muscle differ-
entiation. MEF2-proteins are expressed in a wide range of
tissues, whereas MEF2C is restricted mainly to skeletal mus-
cle, brain, and spleen. However, MEF2C DNA-binding activity
is highly enriched in muscle and neural tissue indicating a
critical role in muscle differentiation.
Positive and negative regulation of eukaryotic transcription
has been shown to be mediated in part by two opposing enzy-
matic activities, histone acetylases and histone deacetylases
* This work was supported by the National Health and Medical
Research Council (NHMRC) of Australia. The Institute for Molecular
Bioscience is part of the Special Research Center for Functional and
Applied Genomics that is supported by Australia Research Council
(ARC). The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
§ Supported by a Postdoctoral Fellowship from the Hochschulsonder-
programm III through the Deutscher Akademischer Austauschdienst
(DAAD), Bonn, Germany).
** Principal Research Fellow of the NHMRC. To whom correspond-
ence should be addressed: Univ. of Queensland, Inst. for Molecular
Bioscience, Ritchie Research Lab., B402A, St. Lucia 4072, Queensland,
Australia. Tel.: 61-7-3365-4492; Fax: 61-7-3365-4388 or 61-7 3279-0640;
E-mail: G.Muscat@imb.uq.edu.au.
1 The abbreviations used are: bHLH, basic helix-loop-helix; HDAC,
histone deacetylase; DMDM, Dulbecco’s modified Eagle’s medium; FCS,
fetal calf serum; HA, hemagglutinin; GST, glutathione S-transferase;
MEF2, myocyte enhancer factor 2; MADS, MCM1-agamous deficiens-
serum response factor; CtBP, C-terminal binding protein.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 276, No. 20, Issue of May 18, pp. 17007–17013, 2001
© 2001 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 17007
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(HDACs) (17, 18). Whereas histone acetylases are associated
with transcriptional activation, deacetylation of histone leads
to a compact chromatin structure to which the accessibility of
transcriptional activators is impaired, and thereby transcrip-
tion is repressed.
Recently, we and others have shown, that the transcriptional
activity of MEF2C is modulated by cofactor recruitment.
MEF2C recruits chromatin remodeling factors such as the his-
tone acetylases p300/CBP and P/CAF (19–22) to activate gene
expression. This recruitment is probably mediated by the coac-
tivator GRIP1, which has been shown to directly interact with
MEF2C and to be necessary for MEF2C-dependent gene ex-
pression and skeletal muscle differentiation (23). Former stud-
ies revealed that GRIP1-mediated activation is due to interac-
tion with p300/CBP and P/CAF (24, 25). Interestingly MEF2
proteins also recruit HDACs, which leads to a repression of
MEF2-dependent gene expression and prevents myogenesis
(26–35). Two families of HDACs, referred to as class-I and
class-II HDACs, have been identified in mammals. Class-I
HDACs (HDAC1, -2, and -3) are related to the yeast transcrip-
tional regulator RPD3 (36–39), are found in large corepressor
complexes (40), and are recruited to MEF2 proteins via core-
pressors such as MITR, Cabin1, and CtBP (26, 27, 33, 34).
Class-II HDACs (HDAC4, -5, -6, and -7) are related to another
yeast transcription factor, Hda1, which was found in a separate
complex from RPD3 (41). HDAC4 and -5 have been reported to
interact directly with MEF2C but also get recruited by core-
pressors (27–29). This interaction is disrupted by the calcium/
calmodulin-dependent kinase CaMK (30, 32, 33, 35), reviewed
in Ref. 42.
In this study we report that the recently identified HDAC7
(43), like other class-II HDACs, represses MEF2-dependent
transcription via physical interaction with the MADS domain
of MEF2. This repression is dependent on the N-terminal re-
pression domain of HDAC7 and functions independently of the
C-terminal deacetylase domain. Furthermore we provide evi-
dence that this functions via the interaction with other core-
pressors, such as CtBP and class-I and -II HDACs. Finally we
demonstrate that the hdac7 mRNA is down-regulated but con-
stitutively expressed during differentiation of muscle cells and
that the HDAC7 protein shuttles from the nucleus into the
cytoplasm during this process thereby preventing the forma-
tion of a MEF2/HDAC7-repressive complex.
EXPERIMENTAL PROCEDURES
Cell Culture and Transient Transfections—Pluripotent C310T1/2
cells were cultured for 24 h in DMEM supplemented with 10% FCS in
6% CO2 before transfection. Cells grown in 12-well plates to 60–70%
confluence were transiently transfected using a DOTAP/DOSPER (3:1)
liposome (Roche Molecular Biochemicals) mixture in HEBS (42 mM
HEPES, 275 mM NaCl, 10 mM KCl, 0.4 mM Na2HPO4, 11 mM Dextrose,
pH 7.1), with 2 mg of total DNA. For elimination of Gal-MEF2C, -A, or
-D-mediated transactivation 1 mg of G5-E1b-Luc reporter, 0.3 mg of the
respective MEF2 cDNA in the pSV40gal expression vector, and 0.6 mg
of HDAC4, -5, or -7 in the pSG5 expression vector/well were used.
Empty expression vectors served as controls. The same conditions
applied for the experiments carried out with Gal-MyoD and
Gal-Myogenin.
For elimination of MEF2C-mediated transactivation on MEF2-re-
sponsive elements, 1 mg of pGL3-MEF2[33]-E1b-Luc reporter (or as
control, the pGL3-E1b-Luc plasmid without MEF2-binding sites), 0.5
mg of pSG5-MEF2C, and 0.5 mg of pSG5-HDAC4, -5, or -7 were used.
Empty SG5 expression plasmid was used as control. Medium was
replaced 24 h after transfection, and cells were further grown for 25–48
h before harvesting and assayed for Luciferase activity using the
Luclite kit (Packard Instrument Co.) according to the manufacturer’s
protocol.
Mouse myogenic C2C12 cells were cultured in growth medium
(DMEM supplemented with 20% FCS) in 6% CO2. For differentiation
assays, cells were grown confluent, and the media was changed into
differentiation medium (DMEM supplemented with 2% horse serum),
and cells were harvested at the time points indicated. For visualizing
intracellular localization of HDAC7, 5 mg of pCMX-HDAC7-YFP were
used to transiently transfect proliferating C2C12 myoblasts held in
growth medium or C2C12 cells that have been grown in differentiation
medium for 48 h. The appropriate medium was replaced after 24 h and
cells were incubated for an additional 24 h. YFP-HDAC7 was visualized
using standard fluorescence procedures after fixation in 4% paraform-
aldehyde in phosphate-buffered solution.
Immunoprecipitation—Cos-7 cells were transfected with expression
constructs encoding either full-length FLAG-tagged MEF2C and HA-
tagged HDAC4, -5, or -7 as indicated using the FuGENE 6 (Roche
Molecular Biochemicals) liposome reagent. 48 h after transfection cells
were lysed in phosphate-buffered solution containing 0.5% Triton
X-100, 150 mM NaCl, 1 mM EDTA, and protease inhibitors (complete by
Roche Molecular Biochemicals) and subjected to brief sonication, and
the resultant cellular debris was pelleted by centrifugation. Lysates
were then incubated with a mouse monoclonal anti-FLAG M2 antibody
(Sigma) for 2 h at 4° C and precipitated by incubation for a further 1 h
FIG. 1. HDAC4, -5, and -7 down-regulate transactivation medi-
ated by MEF2-proteins but not that of myogenic bHLH proteins.
A, pluripotent C310T1/2 cells were transfected with G5-E1b-Luc as a
reporter, pSV40-gal-MEF2C, pSG5-HDAC4, -5, and -7 or the empty
vectors. B, C310T1/2 cells were transfected with the same reporter but
pSV40-gal-MEF2A or -D and pSG5-HDAC4, -5, and -7. Fold activation
is expressed relative to Luciferase activity obtained after cotransfection
of G5-E1b-Luc, pSV40-gal0, and empty pSG5 expression vector alone.
C, pluripotent C310T1/2 cells were transfected with either GL3-
MEF2[33]-E1b-Luc or the GL3-E1b-Luc plasmid with no MEF2 binding
sites as reporter, pSG5-MEF2C, pSG5-HDAC4, -5, and -7 or the empty
pSG5 expression vector. D, pluripotent C310T1/2 cells were transfected
with G5-E1b-Luc as a reporter, pSV40gal-Myogenin or -MyoD, pSG5-
HDAC4, -5, and -7 or the empty vectors. Fold activation is expressed
relative to Luciferase activity obtained after cotransfection of G5-E1b-
Luc, pSV40-gal0, and empty pSG5 expression vector alone.
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with protein A/G affinity resin (Pierce). Precipitated proteins were
resolved by SDS-polyacrylamide gel electrophoresis and subsequently
immunoblotted with a rabbit polyclonal anti-HA antibody (Bab. Co.)
RNA Extraction, Northern Hybridization, and Probe Preparation—
Total RNA was extracted by guanidinium thiocyanate-phenol-chloro-
form method. Northern blots, random priming, and hybridization were
performed as described previously (44, 45). The 1.8-kilobase pair Hin-
dIII fragment of pCMX-m HDAC7-HA (43) was used as a probe for
HDAC7. As a probe for HDAC5 the KpnI/SmaI 1.7-kilobase pair frag-
ment of pCMX-mHDAC5-HA was used. Other cDNA probes have been
described previously (23).
cDNA probes were radioactively labeled by random priming. DNA
fragments (200 ng) were boiled with 20 ng of random hexamers (pdN6;
Amersham Pharmacia Biotech) and then incubated over night with
EcoPol buffer (New England Biolabs), 200 mm dGTP/dTTP, 10 ml
[32P]dATP/[32P]dCTP (Bresatec), and 5–10 units of Klenow polymerase
(New England Biolabs). Probes were purified using NICK columns
(Amersham Pharmacia Biotech) according to the manufacturer’s
protocol.
GST Pulldowns—GST and GST fusion proteins were expressed in
Escherichia coli (BL21) and purified using glutathione-agarose affinity
chromatography as described previously (45, 46). Amounts and integ-
rity of GST fusion proteins were checked by SDS-polyacrylamide gel
electrophoresis and Coomassie staining. The TnT-coupled transcrip-
tion/translation kit (Promega) was used to produce [35S]methionine-
labeled proteins. Pulldowns were carried out as described previously
(23).
RESULTS AND DISCUSSION
HDAC7 Represses MEF2-mediated Transactivation: MyoD
and Myogenin Activity Is Refractory to Class-II HDAC-medi-
ated Inhibition—The class-II HDAC4 and -5 interact with
MEF2 and suppress its ability to activate transcription and cell
specific differentiation (26, 27, 29, 31). Therefore we tested if
the recently discovered HDAC7 (43), which is expressed in a
cell-specific manner and colocalizes with other class-I and -II
HDACs and corepressors in distinct nuclear compartments,
regulates MEF2-mediated transcription.
MEF2C is highly expressed in developing skeletal, cardiac,
and smooth muscle cells. Weak expression is detected in endo-
thelial cells and surrounding mesenchyme during embryo de-
velopment (47–49). Because HDAC7 and MEF2C are ex-
pressed in a similar cell-specific manner, we initially tested the
effect of HDAC7 expression on MEF2C activity.
MEF2C can activate transcription directly and/or by protein-
protein interaction with other DNA bound factors, hence we
examined the effect of HDAC7 (relative to HDAC4 and -5)
expression on MEF2C-mediated transactivation in the GAL4
hybrid system (Fig. 1A). In these assays the activity of MEF2C
is independent of binding to its cognate binding motif, the
A/T-rich MEF2 site. If HDAC7 inhibits the transcriptional
activity, then the potential of the GAL4-MEF2C fusion to
trans-activate gene expression should be significantly reduced
in this assay.
C3H10T1/2 pluripotent cells were cotransfected with GAL-
MEF2C and the G5E1b-LUC reporter in the presence and
absence of the class-II HDAC4, -5, and -7. G5E1b-LUC contains
five copies of the GAL4 binding site placed upstream of a
minimal E1b promoter. Transfection of Gal-MEF2C alone in-
duced transcription ;10-fold relative to the GAL4 DNA bind-
ing domain. This level of activity was significantly repressed by
FIG. 2. HDAC4, -5, and -7 interact
with MEF2C in vivo and in vitro. A,
COS-7 cells were transfected with HA-
tagged HDAC4, -5, and -7 and FLAG-
tagged MEF2C (amino acids 1–117) or the
empty expression vectors as control. Im-
munoprecipitation with a FLAG antibody
followed by Western blot analysis with a
HA antibody show that class-II HDACs
interact with MEF2C in vivo. B, glutathi-
one-agarose-immobilized, bacterial ex-
pressed GST and GST-MEF2C proteins
were incubated with either 35S-radiola-
beled full-length HDAC7 or fragments of
HDAC7 encompassing the indicated
amino acid positions. The input lanes rep-
resent ;20% of total radiolabeled HDAC7
protein. C, schematic representation
showing the HDAC7 regulatory domains
and the deletion fragments used. R1, R2,
repression domains 1 and 2.
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the addition of HDAC4 and -7, whereas no significant effect is
seen on the basal activity of the GAL4-expression plasmid.
Surprisingly, HDAC5 poorly repressed MEF2C activity at the
amounts transfected in this assay.
The MEF2 family is composed of a group of proteins encoded
by four vertebrate genes mef2a, mef2b, mef2c and mef2d (50).
All of these factors bind DNA, recruit cofactors, and trans-
activate gene expression in a similar manner. Hence we ana-
lyzed the effect of HDAC4, -5, and -7 expression on the tran-
scriptional activation mediated by MEF2A and MEF2D (Fig.
1B). Similarly to the results obtained with MEF2C, we ob-
served that HDAC4 and -7 dramatically reduced the activity of
MEF2A and MEF2D. Again, HDAC5 weakly repressed MEF2A
and MEF2D (Fig. 1B). Thus class-II HDACs, including HDAC7,
repress MEF2-dependent gene expression.
The cell culture experiments presented above suggest that
HDAC7 inhibits MEF2 activity. Therefore, we examined
whether HDAC7 repressed MEF2C-dependent activation of a
luciferase reporter with 3 tandem copies of the MEF2 cognate
binding sites upstream of a basal E1b promoter (Fig. 1C). These
experiments clearly demonstrate again that HDAC7 represses
MEF2C-mediated transactivation of a MEF2-dependent re-
porter. The specificity of this repression was supported by the
inability of class-II HDACs alone to repress the MEF2-depend-
ent reporter (MEF2[33]-E1b-LUC) and the failure of MEF2C
and class-II HDACs to regulate the expression of the vehicle,
i.e. the basal E1b promoter linked to luciferase (Fig. 1C).
MEF2 proteins belong to the MADS box family of transcrip-
tion factors that cooperate with the myogenic bHLH proteins,
MyoD and Myogenin, in the activation of the contractile protein
gene expression and function within a regulatory network that
establishes the differentiated phenotype. Therefore, we inves-
tigated whether HDAC7 regulates the transactivation of gene
expression mediated by myogenic bHLH proteins. C310T1/2
cells were transfected with Myogenin or MyoD fused to the
DNA-binding domain of GAL4 and examined for the effect of
class-II HDAC expression on the activity of these transcrip-
tional activators. We observed that neither HDAC4, -5, or -7
had any significant effect on the activity of these bHLH factors
(Fig. 1D).
This data suggest that HDAC7 specifically represses the
activity of the MADS box proteins, MEF2A, -C, and -D, but not
that of the bHLH factors, MyoD and Myogenin. HDAC7 func-
tions as a negative regulator of myogenesis by inhibiting MEF2-
dependent gene expression and transactivation dependent on
the cooperative function between MEF2 and the MyoD family
of basic helix-loop-helix transcription factors. This correlates
with the observations that have been made with HDAC4 and -5
(26, 27, 29, 31).
HDAC7 Interacts with MEF2C: the N-terminal 121 Amino
Acids of HDAC7 Mediate the Interaction—The class-II HDACs
have been reported to directly interact with the N terminus of
MEF2 in vivo and in vitro (26, 27, 29, 31). Therefore we tested
if HDAC7 interacts with MEF2C in vivo. COS-7 cells were
transfected with FLAG-tagged MEF2C (amino acids 1–117),
HA-tagged HDAC7, and the other class-II HDACs (HDAC4 and
-5). Coimmunoprecipitation with the FLAG-antibody demon-
strates that ectopic MEF2C interacts with HA-HDAC7, as well
as with HDAC4 and -5 in vivo (Fig. 2A).
The regulation of MEF2-dependent transcription by the
class-II HDACs and the demonstration of interaction between
FIG. 3. The MADS box of MEF2C is necessary for interaction
with HDAC7. A, schematic representation showing the functional
MEF2C domains and the deletion fragments used. B, glutathione-aga-
rose-immobilized, bacterial expressed GST and GST-HDAC7 proteins
were incubated with either 35S-radiolabeled full-length MEF2C or frag-
ments of MEF2C encompassing the indicated amino acid positions. The
input lanes represent ;10% of total radiolabeled MEF2C protein.
FIG. 4. The deacetylase domain of HDAC7 is not required for
repression of MEF2C-mediated transactivation. A, pluripotent
C310T1/2 cells were transfected with G5-E1b-Luc as a reporter, pSV40-
gal-MEF2C, pSG5-HDAC7, and the indicated mutants of HDAC7 or the
empty vectors. Fold activation is expressed relative to Luciferase activ-
ity obtained after cotransfection of G5-E1b-Luc, pSV40-gal0, and empty
pSG5 expression vector alone. B, the same experiment was performed
but using pSV40-gal0 instead of gal-MEF2C to demonstrate that the
observed repression is MEF2C-dependent.
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these factors in the immunoprecipitation assay strongly sug-
gests that these proteins interact by a direct mechanism. How-
ever, it does not completely eliminate the possibility of an
indirect mechanism in which additional factor(s) mediate the
interaction, although we postulated that HDAC7 represses
MEF2C activity/function by direct interaction. We tested this
hypothesis using a biochemical approach, the in vitro GST
pulldown assay to confirm the direct interaction between
MEF2C and HDAC7.
Glutathione-agarose-immobilized GST-MEF2C was tested
for direct interaction with in vitro 35S-radiolabeled native
HDAC7 (Fig. 2B). Native HDAC7 showed a very strong direct
interaction with GST-MEF2C relative to GST alone, suggest-
ing a direct protein/protein interaction between these two tran-
scription factors as it has been shown for HDAC4 and -5 (29, 31).
To delimit the minimal region of HDAC7 required to mediate
the interaction with MEF2C we incubated a number of 35S-
labeled C-terminal unidirectional deletions of HDAC7 with
GST-MEF2C. We observed that the N-terminal fragment of
HDAC7 encompassing amino acids 1–121 is sufficient to inter-
act with MEF2C (Fig. 2B). This fragment encodes repression
domain 1 of HDAC7 and contains a highly conserved motif of 17
amino acids (Fig. 2C), which has been shown to be necessary for
the interaction of HDAC4 and -5 with the MEF2 proteins (29).
The MADS Box Domain of MEF2C Mediates the Physical
Association with HDAC7—We used the in vitro GST pulldown
assay to confirm the direct interaction between MEF2C and
GST-HDAC7 and to identify the domain in MEF2C that medi-
ates the interaction with this class-II HDAC.
Glutathione-agarose-immobilized GST-HDAC7 was tested
for direct interaction with in vitro 35S-radiolabeled native
MEF2C, MEF2C-(58–465), MEF2C-(90–465), MEF2C-(1–223)
and, MEF2C-(1–177). Native MEF2C showed a very strong
interaction with GST-HDAC7 relative to GST alone. In con-
trast, MEF2C-(58–465) and MEF2C-(90–465) that, respec-
tively, lacked the MADS box and MADS box/MEF2 domains
failed to interact with HDAC7 (Fig. 3). This indicated that the
MADS box is crucial for HDAC7 interaction as it has been
shown for the interaction with HDAC4 and -5 (26, 27, 29, 31).
In support of this result the C-terminal deletions (MEF2C-(1–
223) and, MEF2C-(1–177)) that contained the MADS box effi-
ciently interacted with HDAC7.
Repression of MEF2C-mediated Transcription by HDAC7 Is
Mediated by the N-terminal Repression Domain: the Deacety-
lase Domain Is Not Required—HDACs have been shown to
repress transcription at least partially via deacetylation of
histones but also to harbor other repression domains (43).
FIG. 5. HDAC7 interacts with other corepressors. Glutathione-
agarose-immobilized, bacterial expressed GST and GST-HDAC7 pro-
teins were incubated with either 35S-radiolabeled CtBP or HDAC7
encompassing the indicated amino acid positions. The input lanes rep-
resent ;10% of total radiolabeled protein.
FIG. 6. HDAC7 is constitutively expressed and shuttles into
the cytoplasm during myoblast differentiation. A, total RNA was
isolated from proliferating C2C12 myoblasts (PMB), confluent myo-
blasts (CMB) cultured in growth medium (DMEM containing 20% FCS),
and developing myotubes 4, 8, 24, 72, and 120 h after serum exchange
into differentiation medium (DMEM containing 2% adult horse serum).
After blotting, RNA was probed with 32P-radiolabeled cDNAs encoding
glyceraldehyde-3-phosphate dehydrogenase, HDAC5 and -7, Myogenin,
MyoD, p21, and cyclinD1. Induction of Myogenin and p21 as well as
down-regulation of cyclinD1 confirm that these cells have undergone
terminal differentiation into myotubes. B, C2C12 myoblasts were trans-
fected with HDAC7 fused to the yellow fluorescent protein. Cells kept in
growth medium show an exclusive nuclear staining of HDAC7-YFP.
Cells 72 h after serum withdrawal into differentiation medium show a
cytoplasmatic localization of HDAC7-YFP.
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Therefore we were interested to examine whether the down-
regulation of MEF2-mediated transactivation via HDAC7 re-
quires the enzymatic deacetylation activity. Two deletion mu-
tants of HDAC7 that still interact with MEF2C but lack the
HDAC domain (amino acids 1–372 and 1–121; Fig. 2) and a
point mutation in the HDAC domain that interferes with the
ability to deacetylase histones (H657A, Ref. 51) were tested for
their influence on MEF2C-mediated transactivation. Interest-
ingly, these mutants were also able to inhibit MEF2C-mediated
transactivation and did not interfere with the full-length
HDAC7 (Fig. 4A). No significant effect of HDAC7 mutants or
the full-length construct was observed on the basal activity
when no MEF2C was transfected (Fig. 4B).
Because HDAC7 mutants and deletions lacking deacetylase
function are able to repress MEF2C-mediated transactivation
we wanted to gain an insight in how RD1 and RD2 of HDAC7
mediate repression. We therefore tested if HDAC7 interacts
with other class-I and -II HDACs and corepressors as it has
been shown for HDAC -4 and -5. GST pulldown experiments
using bacterial expressed GST-HDAC7 and in vitro-translated
35S-labeled class-I and -II HDACs or the corepressor CtBP
demonstrate that HDAC7 interacts with all tested HDACs (-1,
-2, -4, -5, and -7) as well as with the corepressor CtBP (Fig. 5).
This observation provides evidence that HDAC7-mediated re-
pression of MEF2 activity requires the recruitment of corepres-
sors and other class-I and -II HDACs.
This is consistent with the identification of a distinct matrix-
associated nuclear structure that contains corepressors
(SMRT, members of the Sin 3 and NuRD complexes), class-I
and -II HDACs (43, 51). Furthermore the interaction of CtBP
with HDAC7 correlates with several observations that demon-
strate that HDAC4, MITR, and Cabin-1 constitute a family of
calcium-sensitive transcriptional repressors of MEF2 and re-
cruit CtBP via the PXDLR motif conserved in the N-terminal
region of HDAC4, -5, and -7 (32–34, 52).
HDAC7 Is Expressed during Skeletal Muscle Differentiation
and Is Regulated via Nucleo-Cytoplasmic Trafficking—To gain
insight into how class-II HDACs regulate MEF2C-dependent
gene activation during muscle differentiation, we examined the
expression pattern of the mRNAs encoding HDAC5 and -7
during the conversion of mouse myoblast C2C12 cells into
terminal differentiated myotubes. Proliferating C2C12 myo-
blasts were induced to biochemically and morphologically dif-
ferentiate into postmitotic, multinucleated myotubes by serum
withdrawal in culture over a period of 4–120 h. Total RNA was
isolated from proliferating myoblasts, confluent myoblasts, and
postmitotic myotubes after 4, 8, 24, 48, 72, and 120 h of serum
withdrawal and examined by Northern blot analysis. The
mRNAs for HDAC7 and -5 are expressed in proliferating myo-
blasts and suppressed as the cells exit the cell cycle and fuse
into terminal differentiated myoblasts that have acquired a
muscle-specific phenotype (Fig. 6A). The repression of the cy-
clinD1 mRNA and the induction of the mRNAs encoding myo-
genin and p21 relative to GAPDH confirms that these cells
were exiting from the cell cycle and activating the differentia-
tion program. However, expression of the class-II HDACs is
still observed in postmitotic cells.
If the HDAC7 protein acts as a transcriptional repressor of
MEF2-mediated gene activation it should be found in the nu-
cleus when MEF2/differentiation-dependant genes are inac-
tive. During myogenesis, when these genes are activated,
HDAC7 should be unable to suppress the function of MEF2 in
the context of HDAC7 expression in postmitotic differentiated
cells. The HDAC7 function as a repressor of MEF2 activity
must be overcome by another mechanism such as cellular traf-
ficking, localization, and/or proteolytic degradation. Observa-
tions reported by others have shown that other class-II HDACs
dissociate from MEF2 proteins and shuttle into the cytoplasm
in differentiation involving calcium/calmodulin and 14–3-3-de-
pendent phosphorylation (27, 29, 32, 35, 42, 52). To address
this question we transfected C2C12 myoblasts with a construct
encoding a fusion protein of HDAC7 and the yellow fluorescent
protein (pCMX-HDAC7-YFP) and examined its sub-cellular lo-
calization in C2C12 cells cultured in growth medium (DMEM
supplemented with 20% FCS) or differentiation medium
(DMEM supplemented with 2% horse serum), which leads to
withdrawal from the cell cycle and the induction of the differ-
entiation program. As seen in Fig. 6B, HDAC7-YFP is predom-
inantly localized in the nucleus when cells were held in growth
medium. After 48 h of serum withdrawal (i.e. culturing in 2%
horse serum), the HDAC7 protein is localized within the cyto-
plasm, where it cannot form an inhibitory complex with MEF2
factors. This observation provides a plausible mechanism for
the regulation of MEF2 function during muscle differentiation:
serum withdrawal leads to nucleo-cytoplasmic trafficking of
HDAC7 and therefore allows the differentiation process to
proceed.
The class-II HDACs are very homologous to each other and
show many similar features in the context of transcriptional
regulation; however, they are different proteins with (i) unique
amino acid sequences and (ii) spatio-temporal-specific expres-
sion patterns. Currently, it still remains unclear what their
specific roles in vivo are and whether functional redundancy
occurs in the class-II HDACs.
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